Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Miriam Möller"'
Autor:
Friederike C. Althoff, Lisa V. Schäfer, Fabian Acker, Lukas Aguinarte, Sophie Heinzen, Maximilian Rost, Akin Atmaca, Vivian Rosery, Jürgen Alt, Cornelius F. Waller, Niels Reinmuth, Gernot Rohde, Felix C. Saalfeld, Aaron Becker von Rose, Miriam Möller, Nikolaj Frost, Martin Sebastian, Jan A. Stratmann
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionSmall cell lung cancer (SCLC) is a rapidly growing malignancy with early distant metastases. Up to 70% will develop brain metastases, and the poor prognosis of these patients has not changed considerably. The potential of checkpoint inhib
Externí odkaz:
https://doaj.org/article/3f16ad1b888741e5ae6ae8361e6b7cfa
Publikováno v:
Cancers, Vol 15, Iss 19, p 4873 (2023)
An important challenge remains in identifying the baseline characteristics of cancer patients who will mostly benefit from immune checkpoint inhibitor (ICI) therapies. Furthermore, biomarkers could help in the choice of an optimal therapy duration af
Externí odkaz:
https://doaj.org/article/e385de97dbdb420db2d79e5bb7999a09
Autor:
Jan A. Stratmann, Radha Timalsina, Akin Atmaca, Vivian Rosery, Nikolaj Frost, Jürgen Alt, Cornelius F. Waller, Niels Reinmuth, Gernot Rohde, Felix C. Saalfeld, Aaron Becker von Rose, Fabian Acker, Lukas Aspacher, Miriam Möller, Martin Sebastian
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Objectives: Small-cell lung cancer (SCLC) is a lung malignancy with high relapse rates and poor survival outcomes. Treatment-resistant disease relapse occurs frequently and effective salvage therapies are urgently needed. Materials and Methods: We ai
Externí odkaz:
https://doaj.org/article/3241382465814be1b90a998fcc16090e
Autor:
Dagmar Riemann, Steffi Turzer, Georgi Ganchev, Wolfgang Schütte, Barbara Seliger, Miriam Möller
Publikováno v:
Biomolecules, Vol 13, Iss 2, p 190 (2023)
In this exploratory prospective observational study on 40 small cell lung cancer (SCLC) patients treated with a combination of chemotherapy and immune checkpoint inhibitors, blood immune cells were characterized by multi-color flow cytometry at the b
Externí odkaz:
https://doaj.org/article/06273a450dcb43fdb77f6061122d3f65
Autor:
Miriam Möller, Steffi Turzer, Georgi Ganchev, Andreas Wienke, Wolfgang Schütte, Barbara Seliger, Dagmar Riemann
Publikováno v:
Cancers, Vol 14, Iss 15, p 3690 (2022)
Although immune checkpoint inhibitor (ICI) therapies have improved the treatment of patients with advanced non-small cell lung cancer (NSCLC), several patients do not achieve durable clinical responses. Biomarkers for the prediction of therapy respon
Externí odkaz:
https://doaj.org/article/955f75b63bae4ca1852f87814ee097d0
Publikováno v:
Cancers, Vol 12, Iss 10, p 2966 (2020)
The aim of this study was to investigate the expression of the coinhibitory molecule PD-L1/CD274 in monocytes and dendritic cells (DC) in the blood of lung cancer patients undergoing PD1 inhibitor therapy and to correlate data with patient’s outcom
Externí odkaz:
https://doaj.org/article/16431961b1ec42289e75e54736f03427
Autor:
Miriam Möller, Wolfgang Schütte
Publikováno v:
Kompass Pneumologie. 11:11-13
Background: Although neoadjuvant anti-PD-1 immunotherapies have shown good efficacy in non-small cell lung cancer (NSCLC) patients, there is still a lack of effective predictive markers. We aimed to develop a pretreatment histologic scoring system to
Publikováno v:
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
Autor:
Wolfgang M, Brueckl, Martin, Reck, Harald, Schäfer, Kai, Neben, Frank, Griesinger, Justyna, Rawluk, Stefan, Krüger, Konrad, Kokowski, Joachim H, Ficker, Miriam, Möller, Andrea, Schueler, Eckart, Laack
Publikováno v:
Journal of Geriatric Oncology. 14:101394
Lung cancer is most common in older patients; despite this, older patients are historically under-represented in clinical studies. Here we present data from GIDEON, a study undertaken in Germany in patients with epidermal growth factor receptor mutat
Autor:
Jan A, Stratmann, Radha, Timalsina, Akin, Atmaca, Vivian, Rosery, Nikolaj, Frost, Jürgen, Alt, Cornelius F, Waller, Niels, Reinmuth, Gernot, Rohde, Felix C, Saalfeld, Aaron Becker, von Rose, Fabian, Acker, Lukas, Aspacher, Miriam, Möller, Martin, Sebastian
Publikováno v:
Therapeutic advances in medical oncology. 14
Small-cell lung cancer (SCLC) is a lung malignancy with high relapse rates and poor survival outcomes. Treatment-resistant disease relapse occurs frequently and effective salvage therapies are urgently needed.We aimed to define efficacy and safety of